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TREATMENT OF HYPERLIPIDEMIA WITH THE ETHYL-ESTER OF 
CHLOROPHENOXYISOBUTYRATE AND ANDROSTERONE 
I R W I N J. SCHATZ, M.D. 
From the Section of Peripheral Vascular Disease, 
Henry Ford Hospital, Detroit, Michigan 
The etiology of atherosclerosis is unknown, but a preponderance of clinical, 
epidemiologic, and experimental evidence supports the thesis that in man elevated 
plasma lipids play a role in its development.' Accordingly, some clinicians have 
concluded that lowering the level of blood fats in patients is an important step in 
the prevention and treatment of atherosclerotic vascular disease. The relationship 
between plasma lipids and atherosclerosis is presumptive only; attempts to lower 
plasma lipids in man have not been proved to prevent or revert atherosclerosis. 
Nevertheless, as Margaret Albrink has said, "Although a 100 per cent certainty does 
not exist, somewhere along the line the results of medical research have to be 
translated into recommendations for action."' 
Many methods of lowering blood fat levels have been devised; the most effective 
and commonly used of these is manipulation of the amount and type of dietary 
fat. Occasionally however, alternative forms of treatment are needed, mainly because 
patients find it difficult to follow dietary instructions conscientiously or because 
the diet itself has failed to lower the blood fats. Consequently, a multitude of oral 
medications have been recommended as hypolipemic drugs. Over f i f ty of these 
compounds have been described,' but none of them has proved ideal. Thus the 
search for a safe and efficacious drug continues. 
I t is known that hormonal factors play a role in the normal variation of serum 
cholesterol in both animals and man. Recently, a series of simple modified estrogen 
compounds (aryloxyisobutyric acids) were administered to animals; the effect on 
serum lipids was studied.^ The most powerful of these in lowering the cholesterol was 
the ethyl-ester of chlorophenoxyisobutyric acid (E-CPIB). 
A spontaneous rhythmic decrease in serum cholesterol is observed normally in 
rats, and also occurs in the human.* This is accompanied by increased adrenal cortical 
and thyroid activity. Since thyroid hormone increases androsterone levels, and it is 
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known that androsterone is hypocholesteremic,^ it has been postulated that andro-
sterone might be the endogenous agent which is responsible for phasic changes in 
cholesterol. 
When androsterone is given to man parenterally it lowers cholesterol, but the 
side-effects of its administration are intolerable. When administered orally in man 
it is ineffective, apparendy because of inactivation in the gastrointestinal tract. How-
ever, with E-CPIB with androsterone is given by mouth hypolipemia results; it is 
not clear if E-CPIB facilitates the absorption of androsterone, but it is known that 
the metabolic action of androsterone is potentiated, perhaps because E-CPIB displaces 
androsterone or its conjugate from plasma proteins. It is possible that increased 
amounts of androsterone accumulate in the liver where its action on hepatic fat 
synthesis results in decreased plasma lipid levels.' 
Obviously, clinical evaluation of this substance is warranted and several reports 
of its efficacy in the treatment of hyperlipidemic states have appeared.'''" No andro-
genic side-effects have been noted either in animals or in man after administration 
of this compound. 
In view of its possible therapeutic value, study of E-CPIB-androsterone* was 
made in a group of outpatients with elevated plasma lipids at the Henry Ford Hospital. 
MATERIAL AND METHOD 
Twenty-six outpatients with elevation of plasma lipids volunteered for this study. 
They were part of a group of outpatients referred for evaluation and treatment of 
various hyperlipidemic states. The only criteria for inclusion in this study were 
the repeated demonstration of elevated levels of plasma lipids and the willingness 
of the patient to participate in a prolonged clinical experiment. Fourteen of this 
group had atherosclerotic vascular disease (Table 1). Multiple control measurements 
of cholesterol, triglycerides and total lipids were made in the postabsorptive state 
(thirty to ninety minutes after eating) during a one to six week period before 
therapy was started, and subsequently every three to four weeks during treatment. 
Multiple measurements on the same samples as well as on samples drawn ten minutes 
a,part were made intermittently during the course of therapy. Serum glutamic oxolacetic 
transaminase (SGOT), leukocyte count, and alkahne phosphatase were measured 
before treatment and then monthly thereafter; in selected patients uric acid, serum 
protein electrophoresis, and bromsulphalein dye retention also were determined monthly. 
After three months of therapy smears of the peripheral blood of each patient were 
examined; subsequently this was done monthly. The patients were instructed to make 
no alteration in their activities, or medications, except for anticoagulant drugs when 
necessary. Two patients with diabetes mellitus continued to adhere to the recommended 
diabetic diet without any major changes during the course of treatment. Other patients 
*Provided as Atromid by John B. Jewell, M.D., Vice President and Medical Director, Ayerst 
Laboratories, New York City, New York. 
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Table I 
Pretreatment Levels* 
Patient Age Sex Diagnosis Cholesterol Triglycerides Total Lipids 
Normal** 
(140-280 mg. 
per cent) 
Normal** 
(40-120 mg. 
per cent) 
Normal** 
(up to 850 mg. 
per cent) 
T.W. 47 M Hypertension 307 241 1765 
H.S. 56 M Generalized 
Atherosclerosis 
408 308 1466 
A.S. 37 M Healthy 436 738 2316 
W.Z. 51 M Generalized 
Atherosclerosis 
432 1025 3979 
G.G. 29 M Healthy 376 66 867 
L . K . 36 M Diffuse 
Atherosclerosis 
362 67 908 
F.D. 56 M Healthy 342 100 953 
S.S. 38 M Coronary 
Atherosclerosis 
447 53 1249 
F.F. 42 M Healthy 350 74 841 
M . H . 43 F Pre-Menopausal; 
Myocardial 
Infarction 
245 126 796 
Q.B. 55 M Coronary 
Atherosclerosis 
273 178 840 
P.Z. 45 M Coronary 
Atherosclerosis 
249 264 988 
A.S. 48 M Coronary 
Atherosclerosis 
273 185 929 
C.J. 52 M Coronary 
Atherosclerosis 
335 138 799 
J.F. 51 M Healthy 312 124 914 
E.F. 52 F Coronary 
Atherosclerosis 
327 220 1218 
R.S. 47 M Healthy 290 152 968 
D.T. 57 F Diabetes 
Mellitus 
320 386 1238 
J.H. 43 M Coronary 
Atherosclerosis 
305 142 909 
D.D. 57 M Healthy 333 173 1036 
L.B. 55 M Healthy 300 128 964 
R.F. 46 M Coronary 
.Atherosclerosis 
265 252 1030 
L.S. 56 M Diabetes 
Mellitus 
Generalized 
Atherosclerosis 
252 1015 1630 
K . M . 47 M Coronary 
Atherosclerosis 
256 479 1195 
**Precision of determination for 95 per cent rehabillty: 
cholesterol: ±8 per cent 
triglycerides: ±8 per cent 
total lipids: ±10 per cent. 
*A11 values are means of multiple measurements. 
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(3.) Total Lipids (Table 4 ) : 
Statistically significant reduction in total lipids was observed in most patients. 
SIDE EFFECTS AND COMPLICATIONS 
A 36 year old male teacher (L.K.) with hypercholesterolemia and severe 
generalized atherosclerosis was given E-CPIB-androsterone on December 11, 1962 
(Table 5). He had been treated previously with nicotinic acid without success. 
Leukopenia and neutropenia occurred on February 5, 1962 during the time of an 
infection with herpes zoster ophthalmicus. Subsequently, intermittent mild leukopenia 
was observed from December 11, 1962 until May 18, 1963; because of this, adminis-
stration of E-CPIB-androsterone was stopped on May 18, 1963. In the ensuing months 
neutropenia with shift to the left became less uitense. Unfortunately the patient was 
lost to follow-up, although the need for further study was made clear to him. He 
returned finally to the clinic on July 13, 1964. A bone marrow examination revealed 
classic changes of chronic lymphocytic leukemia. At the time of writing he has 
no hematologic symptoms. 
Whether the ingestion of E-CPIB-androsterone in this patient played any role 
in the causation of leukemia cannot be answered. It is the opinion of the consulting 
hematologist* that the occurrence of leukopenia and neutropenia on February 5, 1962, 
*Robert K. Nixon, M.D., Medical Clinic #5, Henry Ford Hospital. 
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were requested to adhere to their regular dietary habits and make no significant 
changes ki the amount or type of fat or the number of calories taken. Thus, if a 
low fat diet had been followed prior to therapy this was continued, and if there 
had been no specific diet before treatment, no changes were instituted during therapy. 
Two grams of combined E-CPIB and androsterone were taken daily in the form 
of eight 250 mg. capsules. Each capsule contained 244.5 mg. of E-CPIB and 5.5 mg. 
of androsterone. Cholesterol was measured by an automatic colorimetric technique 
based on methods previously described.' '" Triglycerides were determined by the 
method of Carlson and Wadstrom." Total lipids were calculated by the technique 
of Folch and Van Slyke.'^ 
RESULTS 
(1.) Cholesterol: 
Table 2 lists the results of this treatment on serum cholesterol. 
Statistically significant reduction in levels of cholesterol was observed. 
(2.) Triglycerides (Table 3 ) : 
Considerable individual variation was observed in comparing levels of trigly-
cerides before and during therapy. A statistically significant reduction in tri-
glycerides (P = 0.05) for the entire group occurred. 
TREATMENT OF HYPERLIPIDEMIA 
Table II 
C H O L E S T E R O L * 
Patient Pretreatment Treatment Decrease Months Treated 
T.W. 307 296 11 14 
H.S. 408 297 111 16 
A.S. 436 330 1(16 5 
432 265 167 16 
G.G. 376 295 81 14 
L . K . 362 315 47 7 
F.D. 342 279 63 16 
S.S. 447 395 52 16 
F.F. 350 313 37 6 
M . H . 245 2,18 7 8 
Q.B. 273 250 2,1 11 
P.Z. 249 215 34 16 
A.S. 27.1 297 (-1-24) 10 
C.J. 335 266 69 10 
J.F. .•il2 305 7 16 
E.F. 327 248 79 3 
R.S. 29(1 294 (-^4) 7 
D.T. 32(1 234 86 4 
J.H. ,10.'^  275 30 9 
D.D. 333 279 54 
L.B. 300 280 20 10 
1' 265 295 (+30) 10 
: 252 265 (+13) 16 
'- K . M . 256 26,1 (+7) 13 
Average Decrease = 42 
Significance of Decrease P = 0.001 
*A11 values are means of multiple measurements taken monthly. 
(Normal value is 140-280 mg. per cent.) 
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Table I I I 
TRIGLYCERIDES* 
Patient Pretreatment Treatment Decrease Months T 
T.W. 241 460 (+219) 14 
H.S. 308 214 94 16 
A.S. 738 439 299 5 
W.Z. 1025 204 821 16 
G.G. 66 'H, (+30) 14 
L.K. 67 7,1 (+6) 7 
F.D. 100 83 17 16 
S.S. I4S (+95) 16 
F.F. 74 80 (+6) 6 
M.H. 126 76 50 8 
Q.B. 178 154 24 1 1 
P.Z. 264 113 151 16 
A.S. 185 171 14 10 
C.J. 138 105 33 10 
J.F. 124 67 57 16 
E.F. 220 137 83 3 
R.S. 152 154 (+2) 7 
D.T. ,1S6 94 192 4 
J.H. 142 137 5 9 
D.D. 173 138 35 9 
L.B. 12IS 96 32 10 
R.F. 252 202 ,M) 10 
L.S. 1015 620 395 16 
K.M. 479 283 196 13 
Average Decrease = 91 
Significance of Decrease P = 0.05 
"AH values are means of multiple measurements taken monthly. 
(Normal value is 40-120 mg. per cent.) 
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Table IV 
TOTAL LIPIDS* 
Patient Pretreatment Treatment Decrease Months Treated 
T.W. 1765 1352 413 14 
H.S. 1466 1038 428 16 
A.S. 2316 1517 799 5 
W.Z. 3979 1389 (2590)** 16 
G.G. 867 831 36 14 
L.K. 908 767 141 7 
F.D. 953 869 84 16 
S.S. 1249 1153 96 16 
F.F. ,S41 867 (+26) 6 
M.H. 796 670 126 8 
Q.B. 840 791 49 11 
P.Z. 988 652 336 16 
A.S. 929 448 (+19) 10 
C.J. 799 762 37 10 
J.F. 914 92,1 (+9) 16 
E.F. 1218 755 463 3 
R.S. 968 867 101 7 
D.T. 1238 845 393 4 
J.H. 909 806 10? 9 
D.D. 1036 870 166 9 
L.B. 964 791 17,1 10 
R.F. 1030 1009 21 10 
L.S. 1630 1615 15 16 
K.M. 1195 1003 192 13 
Average Decrease = 179 
Significance of Decrease P = 0.001 
*A11 values are means of multiple measurements taken monthly. 
(Normal value is up to 850 mg. per cent.) 
**Omitted from calculations of average, and of statistical significance. 
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TABLE 5 
4-
PATIENT L.K. 
Year i960 1961 1962 1963 1964 
Date 5-22 11-10 2-5 2-9 12-11 2-11 3-13 5-18 6-6 7-3 9-6 7-15 
WBC/Cubic 
M i l l i m e t e r 7150 8150 3500 7850 4600 17000 2600 5500 3400 5000 54-00 
D i f f e r e n t i a l 
Bands 26 12 5 1 
Neutrophils '^5 70 58 35 40 31 
Eosinophils 2 1 1 if 2 1 
Lymphocytes 55 25 32 48 58 63 
Monocytes 2 1 4 2 
Leukocytoid 
Lymphs 11 2 
T o x i c i t y + 2 + 2 +2 + 1 
Bone Marrow 
Chronic 
Lymphocytic 
Leukemia 
Nico 
5-6 
;inic A 
nn. dai 
cid 
l y 
CPIB 
2 Km. 
. Aiidr< 
d a l l y 
steron e 
Medications 
I l l l l l l l i l l l 
-
TREATMENT OF HYPERLIPIDEMIA 
together with the presence of herpes zoster, indicates a strong likelihood that the 
blood dyscrasia was present, undetected, at that time. Nevertheless, categorical state-
ments excluding or asserting a cause and effect relationship are impossible. It should 
be noted that granulocytopenia has been attributed to E-CPlB-androsterone in one 
patient." In the remaining twenty-three cases of this series, monthly examinations 
and smears of the blood revealed no significant changes of leukopenia or neutropenia. 
Headache was a relatively frequent side-effect, and in one patient was sufficiently 
severe to require cessation of therapy. In this patient the headache was reproduced 
with the administration of the drug. In those three patients in whom significant 
headache occurred simple therapeutic measures with analgesics were sufficient to 
control the symptoms. Pyrosis was obeserved in four patients but was obviated by 
instructions to take the medication after meals. Nightmares, and in other patients 
vivid dreams, were a curious and rather common side-effect, but did not necessitate 
that the drug be stopped. As has been pointed out elsewhere, although there is 
definite potentiation of oral anticoagulant therapy in these patients, this caused no 
significant complications." 
ANCILLARY TESTS 
Control measurements of leukocytes, SGOT, and alkaline phosphatase were 
made in all patients prior to treatment and monthly thereafter. In selected cases, 
uric acid, serum protein electrophoresis, and bromsulphalein dye retention were de-
termined as well. Starting in June of 1963, smears of the peripheral blood were made 
at monthly intervals in all patients. 
A temporary mild rise in SGOT was observed in one patient; it was accompanied 
by an intensification of chronic angina pectoris and by electrocardiographic changes 
compatible with myocardial ischemia. Tests of liver fimction made concomitantly 
were normal. I t is presumed that the increase in SGOT did not reflect hepatotoxicity 
from the drug. 
AU other laboratory tests in all patients were normal, or did not deviate 
significantly from previous levels. 
DISCUSSION 
These results demonstrate that during the administration of E-CPIB-androsterone 
lower levels of blood fats were observed in most patients of this group. The compound 
was most effective in patients with marked elevation of lipids and was less so in those 
with mild to moderate elevations. Continuation of the study over a period of fourteen 
months has shown no tendency for the level of blood fats to return to pretreatment 
levels in those patients in whom a satisfactory response has occurred. 
This confirms the conclusions derived from previous studies''" concerning the 
potential benefits from this compound. Hellman' suggests that E-CPIB alone may be 
effective as the combination of E-CPIB and androsterone. Further comparative clinical 
trials of these drugs obviously are necessary to determine their possible role singly 
and in combination. 
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As was pointed out, whether or not a cause and effect relationship existed 
between the administration of this medication and the subsequent appearance of chronic 
lymphocytic leukemia in one patient cannot be determined. Careful clinical observa-
tion of patients, together with review of pertinent parameters of their hemapoietic 
function is necessary in those receiving this drug. 
CONCLUSIONS 
A combination of E-CPIB-androsterone caused reduction in blood lipid levels 
in most of a group of twenty-four patients. Chronic lymphocytic leukemia was 
detected in one patient subsequent to the administration of this drug, but leukopenia 
and neutropenia had been present at least on one occasion prior tO' its administration. 
Whether any relationship exists between the administration of this drug and the blood 
dyscrasia is unknown. Close observation of all patients receiving this medication 
is necessary for the determination of its eventual role as a hypolipemic medication. 
Mr. David C. Harrison of Ayerst Laboratories, New York City, performed valuable statistical 
analyses. 
Geraldine Fritz, Patricia Miller, Glenda Rouland, Marilyn Jankowiak, and Sonya Lipnick 
provided technical a.ssistance. 
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